Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome
New England Journal of Medicine · 24.09.2026 · 395 (12) · 1193-1205
DOI: 10.1056/nejmoa2515005 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 24.09.2026. Verfasst von Francesca Ferrua und 39 weiteren Autor:innen. Beteiligte Einrichtung: San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan. Hauptthemen laut MEDLINE: Gene Therapy Agents, Genetic Therapy, Hematopoietic Stem Cell Transplantation, Wiskott-Aldrich Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Orchard Therapeutics, GlaxoSmithKline, Fondazione Telethon.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan.
- Pediatric Immunohematology Unit and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan.
- PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome.
- Bicocca Bioinformatics Biostatistics and Bioimaging B4 Center, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
- Biostatistics and Clinical Epidemiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta.
ORCID-Profile: Sabina Cenciarelli
Förderung
- Orchard Therapeutics
- GlaxoSmithKline
- Fondazione Telethon
Zitieren
APA
Ferrua, F., Cenciarelli, S., Giannelli, S., Galimberti, S., Chandrakasan, S., Fraschetta, F., Caputo, C., Sala, D., Monti, I., Barzaghi, F., Calbi, V., Canarutto, D., Consiglieri, G., Doglio, M., Fumagalli, F., Gallo, V., Migliavacca, M., Recupero, S., Tucci, F., …, & WAS Gene Therapy Group (2026). Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome. New England Journal of Medicine, 395(12), 1193-1205. https://doi.org/10.1056/nejmoa2515005
Vancouver
Ferrua F, Cenciarelli S, Giannelli S, Galimberti S, Chandrakasan S, Fraschetta F, et al. Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome. New England Journal of Medicine. 2026;395(12):1193-1205. doi:10.1056/nejmoa2515005
BibTeX
@article{Ferrua2026,
author = {Ferrua, Francesca and Cenciarelli, Sabina and Giannelli, Stefania and Galimberti, Stefania and Chandrakasan, Shanmuganathan and Fraschetta, Federico and Caputo, Carmen and Sala, Davide and Monti, Ilaria and Barzaghi, Federica and Calbi, Valeria and Canarutto, Daniele and Consiglieri, Giulia and Doglio, Matteo and Fumagalli, Francesca and Gallo, Vera and Migliavacca, Maddalena and Recupero, Salvatore and Tucci, Francesca and Orsini, Alessia and Milani, Raffaella and Datukishvili, Mariam and De Gregori, Simona and Montini, Eugenio and Silvani, Paolo and Soncini, Matias and Tomasetto, Elena and van Rossem, Koen and Castagnaro, Laura and Miotto, Federica and Zancan, Stefano and Scotti, Celeste and Russell, Sean and Naldini, Luigi and Ciceri, Fabio and Bernardo, Maria Ester and Parikh, Suhag and Cicalese, Maria Pia and Aiuti, Alessandro and WAS Gene Therapy Group, WAS Gene Therapy Group},
title = {Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {12},
pages = {1193--1205},
doi = {10.1056/nejmoa2515005}
}
EUVIMED